Skip to main content

Table 1 Demographics and clinical features of patients with ILD and a positive anti-Ro52 antibody. Clinical features were compared between patients with anti-Ro52 alone vs anti-Ro52 plus an additional myositis-specific autoantibody (including anti-Jo-1, anti-PL-12, anti-PL-7, anti-EJ, anti-OJ, anti-Mi-2, anti-SRP, anti-MDA5, anti-NXP2, or anti-TIF-1γ)

From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody

Variable All patients
n = 73
Stratified by Autoantibodies
Isolated Anti-Ro52
n = 50
Anti-Ro52 plus myositis-specific autoAb
n = 23
Raw p-value Adjusted p-value*
Age, years median [range] 68 [23–90] 68.5 [23–90] 68 [37–83] 0.75 1.0
Male, n (%) 45 (61.6%) 31 (62%) 14 (60.9%) 0.93 1.0
Ethnicity, n (%)     0.53 1.0
 African American 7 (9.6%) 5 (10%) 2 (8.7%)   
 Asian 6 (8.2%) 3 (6.0%) 3 (13%)   
 Hispanic 4 (5.5%) 2 (4.0%) 2 (8.7%)   
 White 56 (76.7%) 40 (80%) 16 (69.6%)   
Smoking history, n (%)     0.43 1.0
 Current/Former 43 (58.9%) 31 (62%) 12 (52.2%)   
 Never 30 (41.1%) 19 (38%) 11 (47.8%)   
Duration of pulmonary symptoms, n (%)     0.59 1.0
 Acute (<1 week) 9 (12.3%) 7 (14%) 2 (8.7%)   
 Subacute (1 week-6 mo) 14 (19.2%) 8 (16%) 6 (26.1%)   
 Chronic (>6 months) 48 (65.8%) 34 (68%) 14 (60.9%)   
 None 2 (2.7%) 1 (2%) 1 (4.4%)   
ICU admission on presentation, n (%) 13 (17.8%) 10 (20%) 3 (13%) 0.74 1.0
Rheumatologic symptoms, n (%)
 Myalgias 23 (31.5%) 15 (30%) 8 (34.8%) 0.68 1.0
 Mechanic’s hands 10 (13.7%) 3 (6%) 7 (30.4%) 0.01 0.24
 Gottron’s papules 2 (2.7%) 1 (2%) 1 (4.4%) 0.53 1.0
 Heliotrope rash 2 (2.7%) 2 (4%) 0 (0%) 1.0 1.0
 Other rash 13 (17.8%) 7 (14%) 6 (26.1%) 0.32 1.0
 Weight loss 19 (26%) 13 (26%) 6 (26.1%) 0.99 1.0
 Raynaud’s 18 (24.7%) 12 (24%) 6 (26.1%) 0.85 1.0
 Arthralgias 16 (21.9%) 10 (20%) 6 (26.1%) 0.56 1.0
 Sicca symptoms 13 (17.8%) 9 (18%) 4 (17.4%) 1.0 1.0
 Alopecia 5 (6.8%) 4 (8%) 1 (4.4%) 1.0 1.0
 Scleroderma/dactyly 7 (9.6%) 6 (12%) 1 (4.4%) 0.42 1.0
 Any rheum symptoms 49 (67.1%) 35 (70%) 14 (60.9%) 0.44 1.0
 None 24 (32.9%) 15 (30%) 9 (39.1%) 0.44 1.0
Prior CTD diagnosis, n (%)     0.97 1.0
 RA 1 (1.4%) 1 (2%) 0 (0%)   
 Sjogren’s 3 (4.1%) 2 (4%) 1 (4.4%)   
 Scleroderma 4 (5.5%) 3 (6%) 1 (4.4%)   
 SLE 3 (4.1%) 2 (4%) 1 (4.4%)   
 DM/PM 2 (2.7%) 1 (2%) 1 (3.7%)   
 MCTD 3 (4.1%) 3 (6%) 0 (0%)   
 None 57 (78%) 38 (76%) 19 (82.6%)   
Met diagnostic criteria for a CTD, n (%)     0.02 0.48
 Anti-synthetase 5 (6.9%) 0 (0%) 5 (21.7%)   
 DM/PM 5 (6.9%) 3 (6%) 2 (8.7%)   
 MCTD 3 (4.1%) 3 (6%) 0 (0%)   
 PMR 1 (1.4%) 1 (2%) 0 (0%)   
 SLE 2 (2.7%) 1 (2%) 1 (4.4%)   
 Scleroderma 4 (5.5%) 3 (6%) 1 (4.4%)   
 None 53 (72.6%) 39 (78%) 14 (60.9%)   
 Met IPAF criteria, n (%) 36 (49.3%) 27 (54%) 9 (39.1%) 0.24 1.0
  1. *Corrected for multiple comparisons using the step-down Sidak method